BUSINESSCNBC TOP
AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
AstraZeneca's recent trial failure has raised concerns about the vulnerability of its pipeline premium. The company has been valued highly among European pharma firms based on consistent results.
Related Signal
Adjacent reporting
- Major drugmaker loses $27 billion in market value after failed trial
- STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
- AstraZeneca stock plunges after late-stage heart drug trial misses its target
- Godfather of AI blasts Musk's xAI as 'failure,' says labs are risking a 'big bubble explosion'
- ‘Rally on trial’: Bitcoin breakout faces key $80,000 test as whales, ETF investors buy into volatility